<DOC>
	<DOCNO>NCT01235221</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability BIIB041 ( fampridine-sustained release ( SR ) ) treatment Canadian participant multiple sclerosis ( MS ) previously participate registrational extension study conduct Acorda . Those study include NCT00654927 ( MS-F202EXT ) , NCT00648908 ( MS-F203EXT ) NCT00649792 ( MS-F204EXT ) .</brief_summary>
	<brief_title>Open Label Extension Study Evaluate Safety Tolerability Oral Fampridine-Sustained Release ( SR ) Canadian Participants With Multiple Sclerosis Who Participated Acorda Extension Trials .</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Key Inclusion Criteria : 1 . Previously enrol 1 3 Acordasponsored study ( MSF202EXT , MSF203EXT , MSF204EXT ) continue receive fampridineSR . 2 . Willing comply require scheduling assessment protocol . 3 . Female subject childbearing potential , regardless sexual activity , must negative urine pregnancy test , must practice effective contraception study willing able continue contraception 1 month last dose study treatment . Key 1 . Discontinued prematurely precede study ( ( MSF202EXT , MSF203EXT , MSF204EXT ) . 2 . Any prior history seizure , epilepsy , convulsive disorder . 3 . Any clinically significant abnormal laboratory value . 4 . New history moderate severe renal impairment . 5 . New history angina , uncontrolled hypertension , clinically significant cardiac arrhythmia , clinically significant cardiovascular abnormality , judge Investigator . 6 . Any significant change overall health would preclude subject 's participation study , opinion Investigator . 7 . Known allergy pyridinecontaining substance inactive ingredient fampridineSR tablet 8 . Received investigational drug , except fampridineSR precede study ( MSF202EXT , MSF203EXT , MSF204EXT ) , within last 30 day , subject schedule enroll investigational drug time study . 9 . A history drug alcohol abuse within past year . 10 . Treatment form fampridine 4AP ( e.g. , compound formulation 4AP ) 3,4diaminopyridine ( 3,4DAP ) . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>